Clinics in Dermatology
Volume 24, Issue 6 , Pages 536-542 , November 2006

Human immunodeficiency virus infection and pregnancy

References 

  1. Kapoor A, Kapoor A, Vani SN. Prevention of mother to child transmission of HIV. Indian J Pediatr. 2004;71:247–251
  2. Mclntyre J. Mothers infected with HIV. Br Med Bull. 2003;67:127–135
  3. UNAIDS/WHO . In: AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2002;p. 1–42Available at: www.unaids.org[Accessed July 11, 2003]
  4. HIV and AIDS-United states, 1981-2001 . MMWR Morb Mortal Wkly Rep. 2001;50:430–434
  5. Mofenson LM. A critical review of studies evaluating the relationship of role of delivery to prenatal transmission of human immunodeficiency virus. Pediatr Infect Dis J. 1995;14:169–177
  6. Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS. 1998;12:831–837
  7. Coll O, Fiore S, Floridia M, et al. Pregnancy and HIV infection. A European consensus on management. AIDS. 2002;16(Suppl 2):S1–S18
  8. Burns DN, Landesman S, Wright DJ, et al. Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997;175:1206–1210
  9. Guevara H, Casseb J, Zijenah LS, et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr. 2002;29:435–440
  10. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539–545
  11. Frenkel LM, Cowles MK, Shapiro DE, et al. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997;175:971–974
  12. O'Shea S, Newell ML, Dunn DT, et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol. 1998;54:113–117
  13. Arroyo MA, Tien H, Pagan M, et al. Virologic risk factors for vertical transmission of HIV type 1 in Puerto Rico. AIDS Res Hum Retroviruses. 2002;18:447–460
  14. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS. 2000;14:263–271
  15. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394–402
  16. Maiques V, Garcia-Tejedor A, Perales A, et al. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol. 1999;87:63–67
  17. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med. 1996;334:1617–1623
  18. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol. 1995;173:585–589
  19. International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS. 2001;15:357–368
  20. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol. 1996;175:661–667
  21. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis. 1999;179:52–58
  22. Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999;179:319–328
  23. Polycarpou A, Ntais C, Korper BT, et al. Association between maternal and infant class I and II HLA alleles and of their concordance with risk of perinatal HIV type I transmission. AIDS Res Hum Retroviruses. 2002;18:741–746
  24. Tess BH, Rodrigues LC, Newell ML, et al. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS. 1998;12:513–520
  25. Duliege AM, Amos CI, Felton S, et al. Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins: International Registry of Exposed Twins. J Pediatr. 1995;126:625
  26. Newell ML, Dunn DT, Peckham CS, et al. Vertical transmission of HIV-1: maternal immune status and obstetric factors. The European Collaborative Study. AIDS. 1996;10:1675–1681
  27. Semba RD, Miotti PG, Chiphangwi JD, et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet. 1994;343:1593
  28. Burger H, Kovacs A, Weiser B. Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States. J Acquir Immune Defic Syndr. 1997;14:321
  29. Nduati RW, John GC, Richardson BA. Human immunodeficiency virus type 1–infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis. 1995;172:1461
  30. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet. 1999;353:1035–1039
  31. Shapiro D, Tuomala R, Samelson R, et al. Mother-to-child HIV transmission rates according to antiretroviral therapy, mode of delivery, and viral load (PACTG 367). Abstract 114 In: 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002, Seattle, Wash. 2002;
  32. Sitnitskaya Y, Rochford G, Rigaud M, et al. Prevalence of the T215Y mutation in human immunodeficiency virus type 1–infected pregnant women in a New York cohort. 1995-1999. Clin Infect Dis. 2001;33:e3–e37
  33. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951–1957
  34. American College of Obstetricians and Gynecologists . Scheduled caesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion number 234 Washington (DC): American College of Obstetricians and Gynecologists; 2000;
  35. Dunn D, Newell A, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet. 1992;340:585–588
  36. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al. Ghent IAS Working Group on HIV in Women Children Breast-feeding and transmission of HIV-1. J Acquir Immune Defic Syndr. 2004;35:196–202
  37. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999;353:773–780
  38. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–1414
  39. Connor EM, Sperling RS, Gelic R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180
  40. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083–2093
  41. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494
  42. Thorne C, Fiore S, Rudin C. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2003;348:471–472
  43. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003;17:2053–2061
  44. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984–1991
  45. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2000;15:309–320
  46. Grosch-Worner I, Schafer A, Obladen M, et al. Two to four weeks oral maternal and 10 days intravenous neonatal zidovudine prophylaxis and elective caesarean section: effective and safe in reducing vertical transmission of HIV-1 infection. AIDS. 2000;14:2903–2911
  47. Cohan D. Perinatal HIV: special considerations. Top HIV Med. 2003;11:200–213
  48. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995;9:F7–F11

PII: S0738-081X(06)00063-0

doi: 10.1016/j.clindermatol.2006.05.003

Clinics in Dermatology
Volume 24, Issue 6 , Pages 536-542 , November 2006

Article Tools